Taysha Gene Therapies (TSHA) Accumulated Expenses (2019 - 2026)

Taysha Gene Therapies has disclosed Accumulated Expenses across 8 years of filings, most recently posting $15.5 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $15.5 million, up 44.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.5 million (up 44.35% YoY), and the FY2025 annual result was $9.4 million, up 79.8% from the prior year.
• Accumulated Expenses came in at $15.5 million for Q1 2026 at Taysha Gene Therapies, up from $9.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $19.6 million in Q2 2023 to a low of $2.2 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $9.4 million (2025), against an average of $9.7 million.
• Across the five-year window, Accumulated Expenses sank 91.6% in 2022 and jumped 354.75% in 2025, its largest moves.
• Taysha Gene Therapies' Accumulated Expenses stood at $2.5 million in 2022, then jumped by 35.89% to $3.4 million in 2023, then jumped by 53.14% to $5.2 million in 2024, then surged by 79.8% to $9.4 million in 2025, then soared by 64.82% to $15.5 million in 2026.
• The last three Accumulated Expenses figures came in at $15.5 million (Q1 2026), $9.4 million (Q4 2025), and $17.7 million (Q3 2025), per Business Quant data.